This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of -1.72% and 0.19%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Company News for Feb 4, 2020
by Zacks Equity Research
Companies in the news are: GILD, MAXR, INSM, ABG
Insmed (INSM) in Focus: Stock Moves 7.1% Higher
by Zacks Equity Research
Insmed (INSM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of -3.03% and 12.20%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Insmed (INSM) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Insmed (INSM) stock based on the movements in the options market lately.
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of 4.71% and 20.56%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of 0.00% and 0.01%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Top Ranked Momentum Stocks to Buy for May 1st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 1st
Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of -5.41% and 96.19%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Options Traders Expect Huge Moves in Insmed (INSM) Stock
by Zacks Equity Research
Investors need to pay close attention to Insmed (INSM) stock based on the movements in the options market lately.
Insmed (INSM) Wins FDA Nod for Lung Disease Drug Arikayce
by Zacks Equity Research
Insmed's (INSM) lung infection drug Arikayce gains an accelerated approval from the FDA for the treatment of lung disease caused by mycobacterium avium complex (MAC).
Is the Options Market Predicting a Spike in Insmed (INSM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Insmed Incorporated (INSM) stock based on the movements in the options market lately.
Insmed (INSM): Moving Average Crossover Alert
by Zacks Equity Research
Insmed Incorporated (INSM) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
New Strong Sell Stocks for March 1st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Implied Volatility Surging for Insmed Incorporated (INSM) Stock Options
by Zacks Equity Research
Insmed Incorporated (INSM) needs investors to pay close attention to the stock based on moves in the options market lately.
Best Sector ETF of Q3 and its Top-Performing Stocks
by Sweta Killa
Inside the top performing stocks of top U.S.-focused ETF of Q3.
Company News For Sep 6, 2017
by Zacks Equity Research
Companies in the news are: INSM,CLLS,FUL,GOOGL
Insmed Incorporated (INSM) Catches Eye: Stock Soars 119.6%
by Zacks Equity Research
Insmed Incorporated (INSM) was a big mover last session, as the company saw its shares rise nearly 120% on the day amid huge volumes.
Biotech Stock Roundup: Cellectis Down on Clinical Hold, Insmed Soars on Positive Data
by Arpita Dutt
Key highlights include pipeline updates from companies like Cellectis (CLLS) and Insmed. Insmed's shares skyrocketed on positive data from a late-stage study.
Why Did Insmed (INSM) Stock Skyrocket Today?
by Ryan McQueeney
Shares of Insmed Inc. (INSM) more than doubled in pre-market trading Tuesday after the company announced that its new drug, an inhaled antibiotic known as Alis, successfully treated patients with a rare lung disease.
Options Traders Expect Huge Moves in Insmed (INSM) Stock
by Zacks Equity Research
Investors in Insmed (INSM) need to pay close attention to the stock based on moves in the options market lately.
Are Options Traders Betting on a Big Move in Insmed (INSM) Stock?
by Zacks Equity Research
Investors in Insmed (INSM) need to pay close attention to the stock based on moves in the options market lately.
Implied Volatility Surging For Insmed, Inc. (INSM) Stock Options
by Zacks Equity Research
Implied Volatility Surging For Insmed, Inc. (INSM) Stock makes it lucrative to the Option traders.
Options Traders Expect Huge Moves in Insmed (INSM) Stock
by Zacks Equity Research
Insmed (INSM) needs Investors to pay close attention to the stock based on moves in the options market lately.